Fig. 6From: Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLCTumor marker expression pre-vaccination at day 0 and post-vaccination at day 14, 21and 28. a The CEA levels under post-vaccination were decreased compared with pre-vaccination in patient 14. b The levels of CYFRA21 had decreased to normal at post-vaccination compared with pre-vaccination in patient 15Back to article page